186 related articles for article (PubMed ID: 19327923)
21. The Million Women Study--is it believable?
Farmer R
Climacteric; 2005 Sep; 8(3):210-3. PubMed ID: 16390752
[No Abstract] [Full Text] [Related]
22. Tibolone reduces osteoporotic fracture risk and breast cancer risk, but increases the risk of stroke.
de Melo NR; Pompei LM
Gynecol Endocrinol; 2010 Feb; 26(2):73-5. PubMed ID: 19995151
[No Abstract] [Full Text] [Related]
23. Re: Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial.
Wood C; Cline M
J Natl Cancer Inst; 2008 Sep; 100(18):1335; author reply 1335-6. PubMed ID: 18780867
[No Abstract] [Full Text] [Related]
24. Tibolone: the risk is too high.
Goodwin PJ
Lancet Oncol; 2009 Feb; 10(2):103-4. PubMed ID: 19185829
[No Abstract] [Full Text] [Related]
25. Breast cancer risk: is postmenopausal hormone therapy ever safe?
Ganz PA
Menopause; 2005; 12(6):653-5. PubMed ID: 16278604
[No Abstract] [Full Text] [Related]
26. Interaction between hormone replacement therapy preparations and oral anticoagulant therapy.
McLintock LA; Dykes A; Tait RC; Walker ID
BJOG; 2003 Aug; 110(8):777-9. PubMed ID: 12892692
[TBL] [Abstract][Full Text] [Related]
27. Breast cancer and hormonal therapy.
Conner P; Lundström E; von Schoultz B
Clin Obstet Gynecol; 2008 Sep; 51(3):592-606. PubMed ID: 18677153
[TBL] [Abstract][Full Text] [Related]
28. Weighing the risks and benefits of hormone therapy.
Toth S; Blanchard E; Herman L; Larson L; Léger MM; McNellis R; Quigley T; Van Dyke E
JAAPA; 2003 Jun; 16(6):45-7. PubMed ID: 14968505
[No Abstract] [Full Text] [Related]
29. Does tibolone exacerbate atherosclerosis?
Clarkson TB
Eur Heart J; 2006 Mar; 27(6):635-7. PubMed ID: 16415302
[No Abstract] [Full Text] [Related]
30. Long-term effects of tibolone on ocular functions in postmenopausal women.
Verit FF; Oguz H; Ozkul Y; Bozkurt O
Arch Gynecol Obstet; 2007 Apr; 275(4):255-61. PubMed ID: 17047975
[TBL] [Abstract][Full Text] [Related]
31. Carcinoma of the endometrium in patients treated with tibolone.
Yazigi R; Sahid S; Contreras L; Rodriguez T
Gynecol Oncol; 2004 May; 93(2):568-70. PubMed ID: 15099984
[TBL] [Abstract][Full Text] [Related]
32. Livial: a review of clinical studies.
Moore RA
Br J Obstet Gynaecol; 1999 Mar; 106 Suppl 19():1-21. PubMed ID: 10890791
[No Abstract] [Full Text] [Related]
33. Health risks after cessation of postmenopausal hormone therapy.
Pines A; Sturdee D; Birkhäuser M;
Climacteric; 2008 Jun; 11(3):179-80. PubMed ID: 18568782
[No Abstract] [Full Text] [Related]
34. Tibolone and Breast Tissue: a Review.
Lello S; Capozzi A; Scambia G; Franceschini G
Reprod Sci; 2023 Dec; 30(12):3403-3409. PubMed ID: 37450250
[TBL] [Abstract][Full Text] [Related]
35. Ultrastructure study of postmenopausal endometria of tibolone, conjugated estrogen + medroxyprogesterone acetate and tamoxifen users.
Nas T; Sargon MF; Celik HH; Keskin PO; Gürsoy RH; Biberoglu K
Saudi Med J; 2007 Dec; 28(12):1917-9. PubMed ID: 18060233
[No Abstract] [Full Text] [Related]
36. Hormone replacement therapy and breast cancer risk.
Burke CC; Gullatte MM; Vigliani M; Ruggiero RJ; Esserman L; Crawford B
Cancer Pract; 1997; 5(4):203-8. PubMed ID: 9250076
[No Abstract] [Full Text] [Related]
37. Bleeding with menopausal hormone therapy.
Hickey M; Agarwal S
Best Pract Res Clin Obstet Gynaecol; 2009 Feb; 23(1):141-9. PubMed ID: 18977184
[TBL] [Abstract][Full Text] [Related]
38. The Million Women Study and breast cancer.
Speroff L
Maturitas; 2003 Sep; 46(1):1-6. PubMed ID: 12963165
[No Abstract] [Full Text] [Related]
39. Postmenopausal hormone therapy and breast cancer.
Prescrire Int; 2009 Apr; 18(100):66-7. PubMed ID: 19585723
[TBL] [Abstract][Full Text] [Related]
40. E-cadherin expression in cervical epithelial cells of postmenopausal women: association with hormone therapy, tibolone, and raloxifene.
Sioulas V; Christodoulakos G; Lambrinoudaki I; Politi E; Sergentanis TN; Creatsas G
Fertil Steril; 2008 Apr; 89(4):1018-20. PubMed ID: 17689538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
